鉴定六种微小RNA特征作为头颈部鳞状细胞癌患者一种新型潜在的预后生物标志物。
Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma.
作者信息
Shi Hao, Chen Jian, Li Yuncheng, Li Guojun, Zhong Rong, Du Dandan, Meng Ruiwei, Kong Weijia, Lu Meixia
机构信息
Department of Epidemiology and Biostatistics, and The Ministry of Education Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Head and Neck Surgery, Hubei Cancer Hospital, and Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment, Wuhan, Hubei, China.
出版信息
Oncotarget. 2016 Apr 19;7(16):21579-90. doi: 10.18632/oncotarget.7781.
The 5-year survival rate of patients with head and neck squamous cell carcinoma (HNSCC) was only 40%-50%. To investigate the prognostic and predictive value of specific mircoRNAs (miRNAs) in HNSCC. We identified 19 miRNAs associated with over survival (OS) of patients with HNSCC in different clinical classes between 492 HNSCC tissues and 44 normal tissues from The Cancer Genome Atlas (TCGA) dataset. A signature of six miRNAs was identified by the supervised principal component method in the training set. The AUC of the ROC curve for the six microRNA signature predicting 5-year survival was 0.737 (95%CI, 0.627-0.825) in the testing set and 0.708 (95%CI, 0.616-0.785) in the total dataset. In the multivariate Cox regression analysis, patients with high-risk scores had shorter OS (HR, 2.380, 95%CI, 1.361-4.303) than patients with low-risk scores in the total dataset. Therefore, these results provided a new prospect for prognostic biomarker of HNSCC.
头颈部鳞状细胞癌（HNSCC）患者的5年生存率仅为40%-50%。为了研究特定微小RNA（miRNA）在HNSCC中的预后和预测价值。我们从癌症基因组图谱（TCGA）数据集中的492个HNSCC组织和44个正常组织中，鉴定出19种与不同临床分类的HNSCC患者总生存期（OS）相关的miRNA。通过监督主成分法在训练集中鉴定出一个由六种miRNA组成的特征。在测试集中，预测5年生存率的六种微小RNA特征的ROC曲线AUC为0.737（95%CI，0.627-0.825），在总数据集中为0.708（95%CI，0.616-0.785）。在多变量Cox回归分析中，在总数据集中，高风险评分患者的总生存期（HR，2.380，95%CI，1.361-4.303）比低风险评分患者短。因此，这些结果为HNSCC的预后生物标志物提供了新的前景。
Zotero 插件